Medical Daily | Afinitor® in liver cancer does not meet primary endpoint of overall survival Pharmacy Europe Novartis has announced that results of a global Phase III study showed that Afinitor® (everolimus) did not extend overall survival compared to placebo in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) after progression on ... Novartis Drug Afinitor Fails In Tests Against Liver Cancer Novartis drug doesn't extend overall survival of patients with liver cancer Novartis' ambitions for Afinitor suffer on liver-cancer failure |
